However, Medeiros et al. reported that patients with ovarian cancer, who are carriers of glutathione-S-transferase class μ (GSTM1)-null genotype or carriers of non-GSTM1-wt/GSTT1-wt genotypes, when treated with both paclitaxel and cisplatin, present higher mean survival time [59], suggesting a role for GSH in paclitaxel resistance also. Here, GSTM1 is linked to ovarian carcinoma.